Government-funded trial will test psilocybin as treatment for opioid use disorder
Pharmaceutical journal/The pharmaceutical journal January 1, 2024 DOI: 10.1211/pj.2024.1.335169 via OpenAlex
Summary
AI-generated from the abstractA trial in the UK will test whether psilocybin, the active compound in magic mushrooms, can reduce relapse in people recovering from opioid addiction. Led by Imperial College London, the study will include 28 participants who have recently completed detoxification from street opioids. Each participant will receive psilocybin therapy as part of the intervention.
Study at a glance
| Characteristics | Trial Peer reviewed |
|---|---|
| Sample size | 28 |
| Population | People recovering from opioid addiction who have recently undergone detoxification from street opioids |
| Intervention | Psilocybin therapy |
| Key finding | The trial will investigate whether psilocybin therapy can help prevent relapse in people recovering from opioid addiction. |
Abstract
A “UK first” trial will investigate whether psilocybin — the active ingredient in ‘magic mushrooms’ — can help prevent relapse in people recovering from opioid addiction. The psilocybin study, led by researchers at Imperial College London, will involve 28 participants who have recently undergone detoxification from ‘street’ opioids. Participants will receive psilocybin therapy at the […]